Recently, the treatment of lupus-prone NZB/WF1 mice with CD40L antibodies or a combination CTLA4Ig and anti-CD40L reduced circulating B- and T lymphocytes and improved kidney inflammation [48]. This evidence concerns the gene CD40LG and systemic lupus erythematosus.